Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immune-compromised hosts

Cancer Immunology, Immunotherapy

Volumn 54, Issue 12, 2005, Pages 1191-1199

  Ishiguro, Hiroshi ^a   Kishimoto, Takashi ^a   Furuya, Mitsuko ^a   Nagai, Yuichiro ^a   Watanabe, Toru ^b   Ishikura, Hiroshi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

CD40; Immune compromised host; Interleukin 6; Natural killer cell; Nude mouse; Scid mouse

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; IMMUNOGLOBULIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; IMMUNE DEFICIENCY; INOCULATION; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SPLEEN; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; VACCINATION;

ANIMALS; ANTIBODIES; ANTIBODIES, NEOPLASM; ANTIGENS, CD40; CANCER VACCINES; CARCINOMA; CELL LINE, TUMOR; CELL TRANSPLANTATION; DNA, COMPLEMENTARY; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS; INTERLEUKIN-6; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 26244459106     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0695-0     Document Type: Article

References (28)

1. Bouffett E, Phili T, Negrier C, Ffrench M, Frappaz D, Gentilhomme O, Gianella-Borradori A, Brunat-Mentigny M, Blay JY (1997) Phase I study of interleukin-6 in children with solid tumours in relapse. Eur J Cancer 33:1620
2. Diehl S, Chow CW, Weiss L, Palmetshofer A, Twardzik T, Rounds L, Serfling E, Davis RJ, Anguita J, Rincon M (2002) Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. J Exp Med 196:39
3. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531
4. Flinn IW, Ambinder RF (1996) AIDS primary central nervous system lymphoma. Curr Opin Oncol 8:373
5. Galandrini R, Cernetti C, Albi N, Dembech C, Terenzi A, Grignani F, Velardi A (1991) Interleukin-6 is constitutively produced by human CTL clones and is required to maintain their cytolytic function. Cell Immunol 138:11
6. Huang SP, Wu MS, Shun CT, Wang HP, Lin MT, Kuo ML, Lin JT (2004) Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J Biomed Sci 11:517
7. Inoue K, Okabe S, Sueoka E, Sueoka N, Tabei T, Suganuma M (2000) The role of interleukin-6 in inhibition of lung metastasis in subcutaneous tumor-bearing mice. Oncol Rep 7:69
8. Jansen JH, Kluin-Nelemans JC, Van Damme J, Wientjens GJ, Willemze R, Fibbe WE (1992) Interleukin 6 is a permissive factor for monocytic colony formation by human hematopoietic progenitor cells. J Exp Med 175:1151
9. Loeffler S, Fayard B, Weis J, Weissenberger J (2005) Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer (Epub ahead of print)
10. Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E et al (1989) IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol 143:1206
11. Maiman M, Fruchter RG, Serur E, Remy JC, Feuer G, Boyce J (1990) Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 38:377
12. Malejczyk J, Malejczyk M, Urbanski A, Kock A, Jablonska S, Orth G, Luger TA (1991) Constitutive release of IL6 by human papillomavirus type 16 (HPV16)-harboring keratinocytes: a mechanism augmenting the NK-cell-mediated lysis of HPV-bearing neoplastic cells. Cell Immunol 136:155
13. Ming JE, Cernetti C, Steinman RM, Granelli-Piperno A (1989) Interleukin 6 is the principal cytolytic T lymphocyte differentiation factor for thymocytes in human leukocyte conditioned medium. J Mol Cell Immunol 4:203-211
14. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167:332
15. Omi M, Ishikura H, Ishizu A, Takahashi T, Kato H, Yoshiki T (1996) Interleukin (IL)-6 as a pancreas carcinoma-derived vascular permeability regulator in vitro. Pathol Res Pract 192:1107
16. Penn I (1990) Cancers complicating organ transplantation. N Engl J Med 323:1767
17. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L (1993) Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes. J Immunother 14:191
18. Saito K, Ishikura H, Kishimoto T, Kawarada Y, Yano T, Takahashi T, Kato H, Yoshiki T (1998) Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int J Cancer 75:284
19. Scharovsky OG, Binda MM, Rozados VR, Bhagat S, Cher ML, Bonfil RD (2004) Angiogenic and antiangiogenic balance regulates concomitant antitumor resistance. Clin Exp Metastasis 21:177
20. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL (1994) Immune function of patients receiving recombinant human interleukin6 (IL-6) in a phase 1 clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38:119
21. Schuler M, Bruntsch U, Späth-Schwalbe E, Schrezenmeier H, Peschel C, Färber L, Burger KJ, Leißner J, Huber C, Aulitzky WE (1997) Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: result of a phase II study. Eur J Cancer 34:754
22. Stouthard JM, Goey H, de Vries EG, de Mulder PH, Groenewegen A, Pronk L, Stoter G, Sauerwein HP, Bakker PL, Veenhof CH (1996) Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Br J Cancer 73:789
23. Streck C, Zhang Y, Zhou J, Ng CYC, Davidoff A (2004) Endostatin-mediated concomitant resistance in neuroblastoma. J Pediatr Surg 39:405
24. Takai Y, Wong GG, Clark SC, Burakoff SJ, Herrmann SH (1988) B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 140:508
25. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9:4653
26. Ulich TR, del Castillo J, Guo KZ (1989) In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 73:108
27. van Gameren MM, Willemse PHB, Mulder NH, Limburg PC, Groen HJM, Vellenga E, de Vries EGE (1994) Effect of recombinant human interleukin-6 in cancer patients: a phase 1-2 study. Blood 84:1434
28. Yano T, Ishikura H, Kato H, Ogawa Y, Kondo S, Yoshiki T (2001) Vaccination effect of interleukin-6-producing pancreatic cancer cells in nude mice: a model of tumor prevention and treatment in immune-compromised patients. Jpn J Cancer Res 92:83